Genome-wide siRNA screen reveals coupling between mitotic apoptosis and adaptation

Laura A. Díaz-Martínez, Zemfira N. Karamysheva, Ross Warrington, Bing Li, Shuguang Wei, Xian Jin Xie, Michael G. Roth, Hongtao Yu

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The antimitotic anti-cancer drugs, including taxol, perturb spindle dynamics, and induce prolonged, spindle checkpoint-dependent mitotic arrest in cancer cells. These cells then either undergo apoptosis triggered by the intrinsic mitochondrial pathway or exit mitosis without proper cell division in an adaptation pathway. Using a genome-wide small interfering RNA (siRNA) screen in taxol-treated HeLa cells, we systematically identify components of the mitotic apoptosis and adaptation pathways. We show that the Mad2 inhibitor p31comet actively promotes mitotic adaptation through cyclin B1 degradation and has a minor separate function in suppressing apoptosis. Conversely, the pro-apoptotic Bcl2 family member, Noxa, is a critical initiator of mitotic cell death. Unexpectedly, the upstream components of the mitochondrial apoptosis pathway and the mitochondrial fission protein Drp1 contribute to mitotic adaption. Our results reveal crosstalk between the apoptosis and adaptation pathways during mitotic arrest. Synopsis Prolonged mitotic arrest induced by anti-proliferative drugs eventually results in apoptotic cell death or in mitotic exit due to checkpoint adaptation. An RNAi screen in human cancer cells lines offers new insights into the regulatory networks underlying these processes. Genome-wide siRNA screen identifies regulators of mitotic cell death and checkpoint adaptation. The BH3-only protein Noxa promotes apoptosis during mitotic arrest. The spindle checkpoint regulator p31comet suppresses mitotic adaptation and facilitates apoptosis. A Bax/Bak mitochondrial module couples mitotic apoptosis and adaptation. The mitochondrial fission factor Drp1 promotes mitotic checkpoint adaptation. An RNAi screen offers new insights into the regulatory networks governing the fate of cancer cells undergoing prolonged drug-induced mitotic checkpoint arrest.

Original languageEnglish (US)
Pages (from-to)1960-1976
Number of pages17
JournalEMBO Journal
Volume33
Issue number17
DOIs
StatePublished - Sep 1 2014

Fingerprint

Small Interfering RNA
Genes
Genome
Apoptosis
M Phase Cell Cycle Checkpoints
Cell death
Cells
Noxae
Mitochondrial Dynamics
Cell Death
RNA Interference
Paclitaxel
Neoplasms
Pharmaceutical Preparations
Cyclin B1
Antimitotic Agents
Mitochondrial Proteins
Crosstalk
HeLa Cells
Mitosis

Keywords

  • apoptosis
  • mitochondria
  • mitosis
  • mitotic slippage
  • the spindle checkpoint

ASJC Scopus subject areas

  • Molecular Biology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Neuroscience(all)

Cite this

Genome-wide siRNA screen reveals coupling between mitotic apoptosis and adaptation. / Díaz-Martínez, Laura A.; Karamysheva, Zemfira N.; Warrington, Ross; Li, Bing; Wei, Shuguang; Xie, Xian Jin; Roth, Michael G.; Yu, Hongtao.

In: EMBO Journal, Vol. 33, No. 17, 01.09.2014, p. 1960-1976.

Research output: Contribution to journalArticle

Díaz-Martínez, Laura A. ; Karamysheva, Zemfira N. ; Warrington, Ross ; Li, Bing ; Wei, Shuguang ; Xie, Xian Jin ; Roth, Michael G. ; Yu, Hongtao. / Genome-wide siRNA screen reveals coupling between mitotic apoptosis and adaptation. In: EMBO Journal. 2014 ; Vol. 33, No. 17. pp. 1960-1976.
@article{130600c0e97b4b8f91b80ab896e4399b,
title = "Genome-wide siRNA screen reveals coupling between mitotic apoptosis and adaptation",
abstract = "The antimitotic anti-cancer drugs, including taxol, perturb spindle dynamics, and induce prolonged, spindle checkpoint-dependent mitotic arrest in cancer cells. These cells then either undergo apoptosis triggered by the intrinsic mitochondrial pathway or exit mitosis without proper cell division in an adaptation pathway. Using a genome-wide small interfering RNA (siRNA) screen in taxol-treated HeLa cells, we systematically identify components of the mitotic apoptosis and adaptation pathways. We show that the Mad2 inhibitor p31comet actively promotes mitotic adaptation through cyclin B1 degradation and has a minor separate function in suppressing apoptosis. Conversely, the pro-apoptotic Bcl2 family member, Noxa, is a critical initiator of mitotic cell death. Unexpectedly, the upstream components of the mitochondrial apoptosis pathway and the mitochondrial fission protein Drp1 contribute to mitotic adaption. Our results reveal crosstalk between the apoptosis and adaptation pathways during mitotic arrest. Synopsis Prolonged mitotic arrest induced by anti-proliferative drugs eventually results in apoptotic cell death or in mitotic exit due to checkpoint adaptation. An RNAi screen in human cancer cells lines offers new insights into the regulatory networks underlying these processes. Genome-wide siRNA screen identifies regulators of mitotic cell death and checkpoint adaptation. The BH3-only protein Noxa promotes apoptosis during mitotic arrest. The spindle checkpoint regulator p31comet suppresses mitotic adaptation and facilitates apoptosis. A Bax/Bak mitochondrial module couples mitotic apoptosis and adaptation. The mitochondrial fission factor Drp1 promotes mitotic checkpoint adaptation. An RNAi screen offers new insights into the regulatory networks governing the fate of cancer cells undergoing prolonged drug-induced mitotic checkpoint arrest.",
keywords = "apoptosis, mitochondria, mitosis, mitotic slippage, the spindle checkpoint",
author = "D{\'i}az-Mart{\'i}nez, {Laura A.} and Karamysheva, {Zemfira N.} and Ross Warrington and Bing Li and Shuguang Wei and Xie, {Xian Jin} and Roth, {Michael G.} and Hongtao Yu",
year = "2014",
month = "9",
day = "1",
doi = "10.15252/embj.201487826",
language = "English (US)",
volume = "33",
pages = "1960--1976",
journal = "EMBO Journal",
issn = "0261-4189",
publisher = "Nature Publishing Group",
number = "17",

}

TY - JOUR

T1 - Genome-wide siRNA screen reveals coupling between mitotic apoptosis and adaptation

AU - Díaz-Martínez, Laura A.

AU - Karamysheva, Zemfira N.

AU - Warrington, Ross

AU - Li, Bing

AU - Wei, Shuguang

AU - Xie, Xian Jin

AU - Roth, Michael G.

AU - Yu, Hongtao

PY - 2014/9/1

Y1 - 2014/9/1

N2 - The antimitotic anti-cancer drugs, including taxol, perturb spindle dynamics, and induce prolonged, spindle checkpoint-dependent mitotic arrest in cancer cells. These cells then either undergo apoptosis triggered by the intrinsic mitochondrial pathway or exit mitosis without proper cell division in an adaptation pathway. Using a genome-wide small interfering RNA (siRNA) screen in taxol-treated HeLa cells, we systematically identify components of the mitotic apoptosis and adaptation pathways. We show that the Mad2 inhibitor p31comet actively promotes mitotic adaptation through cyclin B1 degradation and has a minor separate function in suppressing apoptosis. Conversely, the pro-apoptotic Bcl2 family member, Noxa, is a critical initiator of mitotic cell death. Unexpectedly, the upstream components of the mitochondrial apoptosis pathway and the mitochondrial fission protein Drp1 contribute to mitotic adaption. Our results reveal crosstalk between the apoptosis and adaptation pathways during mitotic arrest. Synopsis Prolonged mitotic arrest induced by anti-proliferative drugs eventually results in apoptotic cell death or in mitotic exit due to checkpoint adaptation. An RNAi screen in human cancer cells lines offers new insights into the regulatory networks underlying these processes. Genome-wide siRNA screen identifies regulators of mitotic cell death and checkpoint adaptation. The BH3-only protein Noxa promotes apoptosis during mitotic arrest. The spindle checkpoint regulator p31comet suppresses mitotic adaptation and facilitates apoptosis. A Bax/Bak mitochondrial module couples mitotic apoptosis and adaptation. The mitochondrial fission factor Drp1 promotes mitotic checkpoint adaptation. An RNAi screen offers new insights into the regulatory networks governing the fate of cancer cells undergoing prolonged drug-induced mitotic checkpoint arrest.

AB - The antimitotic anti-cancer drugs, including taxol, perturb spindle dynamics, and induce prolonged, spindle checkpoint-dependent mitotic arrest in cancer cells. These cells then either undergo apoptosis triggered by the intrinsic mitochondrial pathway or exit mitosis without proper cell division in an adaptation pathway. Using a genome-wide small interfering RNA (siRNA) screen in taxol-treated HeLa cells, we systematically identify components of the mitotic apoptosis and adaptation pathways. We show that the Mad2 inhibitor p31comet actively promotes mitotic adaptation through cyclin B1 degradation and has a minor separate function in suppressing apoptosis. Conversely, the pro-apoptotic Bcl2 family member, Noxa, is a critical initiator of mitotic cell death. Unexpectedly, the upstream components of the mitochondrial apoptosis pathway and the mitochondrial fission protein Drp1 contribute to mitotic adaption. Our results reveal crosstalk between the apoptosis and adaptation pathways during mitotic arrest. Synopsis Prolonged mitotic arrest induced by anti-proliferative drugs eventually results in apoptotic cell death or in mitotic exit due to checkpoint adaptation. An RNAi screen in human cancer cells lines offers new insights into the regulatory networks underlying these processes. Genome-wide siRNA screen identifies regulators of mitotic cell death and checkpoint adaptation. The BH3-only protein Noxa promotes apoptosis during mitotic arrest. The spindle checkpoint regulator p31comet suppresses mitotic adaptation and facilitates apoptosis. A Bax/Bak mitochondrial module couples mitotic apoptosis and adaptation. The mitochondrial fission factor Drp1 promotes mitotic checkpoint adaptation. An RNAi screen offers new insights into the regulatory networks governing the fate of cancer cells undergoing prolonged drug-induced mitotic checkpoint arrest.

KW - apoptosis

KW - mitochondria

KW - mitosis

KW - mitotic slippage

KW - the spindle checkpoint

UR - http://www.scopus.com/inward/record.url?scp=84906834987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906834987&partnerID=8YFLogxK

U2 - 10.15252/embj.201487826

DO - 10.15252/embj.201487826

M3 - Article

VL - 33

SP - 1960

EP - 1976

JO - EMBO Journal

JF - EMBO Journal

SN - 0261-4189

IS - 17

ER -